May 1, 2018

credentis secures global distribution partner for CURODONT™ REPAIR

credentis announced today that it has signed a non-exclusive distribution agreement with a global dental company for its unique non-invasive caries therapy CURODONT™ REPAIR.

With a strong marketing and sales partner on board, this unique product for Guided Enamel Regeneration is to be launched later in the year as a key portfolio element for caries prevention and early treatment. The partner company will be named at a later date.

Staged marketing operations will begin in Germany, Italy, United Kingdom, Canada and the United States.

We are convinced that this partnership with a dental leader committed to innovation and  preventive dentistry, is the ideal way to establish the CUROLOX® TECHNOLOGY in the dental world.” says Dominik Lysek, CEO and founder of credentis ag.

credentis ag will continue to sell the CURODONT™ product portfolio directly to its customers. More details will be disclosed closer to the launch date.

Read this on as PDF.

Link to our European CURODONT webpage.
Link to the CREDENTIS homepage.

CURODONT™ REPAIR is marketed in Switzerland under the brand name REGENAMEL®



The patented CUROLOX® TECHNOLOGY is based on self-assembling peptides, which form a 3-dimensional matrix with high affinity for the dental mineral.
In pure form, CUROLOX® TECHNOLOGY is used in CURODONT™ REPAIR as a crystallization nucleus for new hydroxyapatite crystals. This gives dentists a non-invasive way to regenerate caries lesions and similar dental defects – Guided Enamel Regeneration (GER).
CURODONT ™ D’SENZ is designed for the treatment of sensitive teeth. It utilizes the high bonding capacity of the CUROLOX® TECHNOLOGY to the tooth surface to form an effective protective barrier on the dentin. This quickly protects against painful stimuli.
CURODONT™ PROTECT uses CUROLOX® TECHNOLOGY, to effectively protect the enamel against acid.


About credentis ag

Headquartered in Switzerland, credentis is focused on the development and market introduction of advanced dental solutions based on its patented and award winning CUROLOX® TECHNOLOGY. Active in both medical device- and cosmetic- industry, credentis has a proven track record of innovative products and a strong university network.

Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. Credentis highly experienced board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.